MRK: Pipeline Bet Gets Cheaper at 15x Earnings
Key Takeaways
- MRK trades at 15.7x trailing PE — a discount to pharma peers that reflects the 2028 Keytruda patent cliff.
- Full-year 2025 revenue hit $65 billion with gross margins averaging 78-80%, and forward estimates project $71 billion by 2027.
- The Q4 2025 EPS drop to $1.19 was driven by a $5.3 billion non-operating charge, not business deterioration.
- Merck's pipeline includes 20+ growth drivers, combo therapy wins in kidney and bladder cancer, and Moderna mRNA vaccine trials.
Merck trades at $114.18 — a 15.7x trailing PE and 9% below its 52-week high of $125.14. For a company generating $65 billion in annual revenue with 77% gross margins, that multiple screams either opportunity or trap.
The answer depends entirely on Keytruda. Merck's blockbuster cancer drug generated the bulk of its oncology revenue in 2025, and patent exclusivity expires in 2028. Two years isn't a long runway. But Merck isn't standing still: it's splitting its human-health business into two divisions, advancing 20+ pipeline candidates, and partnering with Moderna on personalized mRNA cancer vaccines now entering Phase 3 trials.
At $282 billion in market cap, the market is pricing in significant erosion. The question is whether it's pricing in too much.
Valuation: Cheap for a Reason, But Maybe Too Cheap
Merck's 15.7x PE sits well below the S&P 500 average and at a discount to pharma peers like Eli Lilly (trading above 60x) and AbbVie (around 20x). The price-to-book ratio of 4.98x reflects the asset-light nature of pharmaceutical businesses, while the EV/EBITDA of 68.7x looks inflated by a Q4 2025 charge that depressed trailing numbers.
The forward picture tells a different story. Analysts expect quarterly EPS of $2.16-$2.62 through 2027, implying annualized earnings around $9.50. That puts the forward PE closer to 12x — genuine value territory for a company with Merck's cash generation.
The Q4 EPS collapse to $1.19 from $2.32 in Q3 was driven by $5.3 billion in non-operating charges, not deteriorating business performance. Strip that out and trailing earnings power looks closer to $8.50-$9.00.
Earnings: Revenue Machine With a Q4 Distortion
Full-year 2025 revenue hit $65 billion across four quarters: $15.5B (Q1), $15.8B (Q2), $17.3B (Q3), and $16.4B (Q4). The Q3 spike reflects typical seasonality in oncology treatment cycles.
Gross margins remained exceptional — 92.7% in Q4 and averaging 78-80% across the full year when excluding one-time items. Operating income ran at $5.5-$8.7 billion per quarter, funding $3.6-$4.2 billion in R&D spending (22-25% of revenue). That R&D intensity is critical: it's the bridge to a post-Keytruda future.
Net income for the full year was approximately $18.3 billion, yielding trailing EPS of $7.28. The company maintained its dividend at roughly $0.81 per quarter — a 2.8% yield at current prices with a manageable 68% payout ratio.
Financial Health: Leveraged But Manageable
Merck carries $50.3 billion in total debt against $14.5 billion in cash, giving a net debt position of roughly $35.8 billion. The debt-to-equity ratio of 0.96x is elevated but standard for big pharma companies that finance acquisitions with leverage.
The current ratio of 1.54x provides adequate liquidity, and operating cash flow of approximately $6.6 billion through the first half of 2025 demonstrates the business can service its obligations comfortably. Free cash flow yield of roughly 3.3% on the current market cap isn't exciting, but it's sufficient to cover the dividend and fund pipeline development.
The real balance sheet risk is intangible-heavy: 35% of total assets sit in goodwill and intangibles from past acquisitions. If pipeline drugs fail, those write-downs could be material.
The Keytruda Cliff and What Comes After
Keytruda's patent expiration in 2028 is the single largest risk factor in pharma today. Biosimilar competition will erode revenue rapidly — the question is how much Merck can offset through new approvals.
The pipeline looks credible. In late February 2026, Merck reported positive late-stage data across kidney, ovarian, and bladder cancers. The LITESPARK-022 trial showed KEYTRUDA plus WELIREG cut recurrence or death versus KEYTRUDA alone in adjuvant clear cell renal cell carcinoma — extending the franchise into earlier-stage treatment.
The Moderna partnership on personalized mRNA cancer vaccines is perhaps the most intriguing optionality. Five-year data supports the approach, and Phase 3 trials are underway. If successful, this could represent an entirely new revenue stream rather than just a Keytruda extension.
Merck is also restructuring, splitting its human-health business into two divisions to sharpen focus and accountability as it manages the transition. Management has identified 20+ growth drivers across oncology and cardiovascular therapies.
Forward Outlook: Analysts See Upside
Consensus estimates project quarterly revenue of $16.8-$18.8 billion through 2027, suggesting the street expects modest growth even as Keytruda erosion begins. Annualized 2027 revenue estimates of roughly $71 billion would represent 9% growth from 2025.
Institutional activity has been mixed. CIBC Private Wealth trimmed its position by 3.9% (selling 16,094 shares), while CIBC Bancorp opened a new 345,081-share position worth $29 million. The divergence suggests institutions are repositioning rather than fleeing.
The next earnings report on April 30 will provide critical updated guidance on Keytruda trajectory and pipeline timelines. Any acceleration in regulatory approvals for combo therapies could catalyze a re-rating.
Conclusion
Merck at 15.7x trailing earnings offers genuine value — but it's value with a countdown timer. The Keytruda patent cliff in 2028 is real, and no amount of pipeline optimism eliminates that risk entirely.
The bull case is straightforward: at 12x forward earnings with a 2.8% dividend yield, the downside is limited and the pipeline optionality is essentially free. The bear case is equally clear: biosimilar erosion could be faster than expected, and no single pipeline drug will replace a franchise this large.
Own it if you can tolerate the transition risk. The 52-week low of $73.31 is unlikely to return given current earnings power, and a move back toward $125 is plausible if pipeline data continues to deliver. Avoid if you need certainty about 2028 and beyond.
Frequently Asked Questions
Sources & References
www.sec.gov
simplywall.st
Disclaimer: This content is for informational purposes only and does not constitute financial advice. Consult qualified professionals before making investment decisions.